7 results
The objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response and blood counts and can be use as front-line therapy for SAA treatment.
To provide continuing treatment with eltrombopag for subjects who are currently participating in a GSK sponsored investigational study of eltrombopag (parent study) and to collect long term safety data.
Optimizing orthotic management in children with cerebral palsy to improve mobility and participation
The primary objective of this study is to evaluate AFO efficacy in children with spastic CP using outcome measures related to ICF the components of *body functions and structures* and *activities and participation*. The secondary aim is to identify…
Part 1 (open-label, 8 week): safety and tolerability of eltrombopag, optimal dose escalation scheme for use in Part 2, PK.Part 2: Primary: the reduction in the number of clinically relevant thrombocytopenic events (*Grade 3 hemorrhagic adverse…
The aim of the clinical trial is to evaluate Hybrid-APC as a thermal ablation therapy for the treatment of BE following preceded endoscopic resection (ER) or as a primary therapy for neoplasia that are initially not detectable using high resolution…
To determine whether AFOs optimized for stiffness in patients with calf muscle weakness are superior to standard AFOs in reducing walking effort, as measured by energy cost of walking (ECW, in Jkg-1m-1), and 2) to build a model to predict required…
- To evaluate the relative bioavailability between the new eltrombopag capsule formulation (CPS) and the marketed tablet formulation (FCT) at single oral doses of 25 mg and 75 mg, in healthy subjects in the fasted state.- To evaluate the PK…